Suven Life Sciences Ltd
Smt. J.A.S. Padmaja aged 56 years is a Psychology graduate from St. Francis College Hyderabad and a post graduate Diploma in Marriage and Family Counseling from Osmania University.
She is involved in various social service activities for over 3 decades. She is a practicing counselor for the last twenty years working with mental disorders, adolescent crisis, depression and anxiety disorders and marriage counseling.
She was actively involved in founding THE HYDERABAD CHILDRENS TRUST (HCT) which gives meaningful life to the orphaned children by providing shelter and education so that they can secure decent jobs and lead a normal life.
She was also associated with APWMR as Vice President - which took up various welfare activities for differently abled children. She is associated with the JVMRD Trust as a chairperson where she is involved in building a high school in a remote village of the most backward area of AP.
She is also associated with skill development programs for women and educated youth requiring further skills to make them employable from this backward area through this Trust.
This person is not in the org chart
This person is not in any offices
Suven Life Sciences Ltd
1 followers
Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company's segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS), which consists of collaborative research projects (CRP), clinical trials, and testing and analysis services, and Research and Development. Its products consist of active pharmaceutical ingredients (APIs), including Aripiprazole, Armodafinil, Calcium Acetate, Carprofen, Deferasirox, Doxofylline, Entacapone, Fenoprofen Calcium, Rosuvastatin Calcium, Sitagliptin Phosphate and Solifenacin succinate, and intermediates, including 2-nitro phenyl acetic acid and 3, 4-dichlorobenzylamine. The Company is engaged in the drug discovery specializing in central nervous system (CNS)-based programs with over four of the molecules in pipeline under clinical phase of development.